Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Contact Us
Contact Us

Newsroom

Newsroom

Industry News
Antheia Inc., Menlo Park, $73 million: Viking Global Investors led the Series B funding of this company that's making plant-based medicines using synthetic biology. Sherpalo...
Industry News
Synthetic biology startup Antheia raised $73 million in Series B financing to support the company’s efforts to bring its first plant-based medicine to market and...
Industry News
The idea: A California company producing active pharmaceutical ingredients with engineered yeast raised $73 million to bring its first product to market......
Industry News
Any doubts about synthetic biology’s attractiveness to investors were likely shattered during the first quarter, when investors pumped $4.6 billion into such companies—more than four...
Industry News
Synthetic biology startup Antheia raised $73 million in Series B financing to support the company’s efforts to bring its first plant-based medicine to market and...
Industry News
The age of synthetic biology is officially upon us with super-unicorns like Ginkgo Bioworks changing the game in terms of how investors view those cell...
Blog Posts
Technology today is defined by superlatives: we have the fastest cars, the best medicine, and the most advanced communication tools ever known. Yet despite humanity’s...
Blog Posts
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, today announced the appointment of Heidi Pucel as its Chief People Officer. Pucel joins the company...
Blog Posts
Antheia is at a critical point in scaling our production technology. Just as we bring together exceptional science and technologies to unleash the power of...
Blog Posts
Synthetic biology isn’t a household name - yet. But it will be soon, because it’s a thriving, innovative field that’s solving some of humanity’s greatest...
Blog Posts
Global health experts and governing bodies agree that everyone has a right to access the medicines they need. The COVID-19 pandemic and resulting drug shortages...
Blog Posts
The global pandemic has brought pharmaceutical manufacturing to the forefront of America’s public consciousness. Acute drug shortages brought on by COVID-19 have underscored the need...

See our media kit

Antheia Secures Second BioMaP-Consortium Project Valued at $12M